{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:07Z","timestamp":1760144227548,"version":"build-2065373602"},"reference-count":56,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background and Aims: The presence of portal hypertension in cirrhotic patients is a major prognostic factor associated with the development of severe complications and increased mortality. The gold standard for diagnosing portal hypertension is the hepatic venous pressure gradient. More recently, spleen stiffness has emerged as a new and non-invasive diagnostic tool, and has already been included in the last Baveno VII guidelines. The exact prevalence of Helicobacter pylori infection, pre-malignant lesions and their relation to portal hypertension have never been described. The aim of our study was to evaluate the relationship between the presence of portal hypertension assessed via liver and spleen elastography and Helicobacter pylori infection and pre-malignant gastric lesions. Methods: An observational study was conducted, including consecutive patients admitted from December 2020 to December 2022. All patients underwent upper endoscopy and were also subjected to liver and spleen elastography (using the new probe of 100 Hz) by the same blinded operator in a tertiary center. Results: We included 155 cirrhotic patients, with a mean age of 64.1 years (\u00b18.8), and 81.3% were male. The most common etiology was alcoholic liver disease (72.9%). The median value of liver stiffness measurement was 24.4 kPa [3.1\u201375.0], and the spleen stiffness measurement was 49.1 kPa [12.8\u2013100.0]. Akin to endoscopic findings, 50.3% presented esophageal varices, 5.2% gastric atrophy, 11.6% gastric metaplasia, and 32.9% portal hypertension gastropathy. Regarding histologic findings, we found that 34.8% presented H. pylori infection, 35.5% gastric atrophy (OLGA 1\u201458.2%) and 38.7% gastric metaplasia (OLGIM 1\u201463.3%). Liver stiffness and spleen stiffness measurements were associated with the presence of portal hypertensive gastropathy (p &lt; 0.01), but not with H. pylori infection or pre-malignant gastric lesions. Conclusions: Although present in almost one third of cirrhotic patients, H. pylori infection and pre-malignant gastric lesions are not associated with liver stiffness and spleen stiffness measurements. On the other hand, we found an association between liver stiffness and spleen stiffness measurements and portal hypertensive gastropathy.<\/jats:p>","DOI":"10.3390\/jcm13061768","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T05:04:12Z","timestamp":1710911052000},"page":"1768","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does Portal Hypertension Increase the Risk of Helicobacter pylori Infection and Pre-Malignant Gastric Lesions?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0332-3844","authenticated-orcid":false,"given":"Rui","family":"Gaspar","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology, Unidade Local de Sa\u00fade de S\u00e3o Jo\u00e3o, Porto 4200, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-5635","authenticated-orcid":false,"given":"Pedro","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Unidade Local de Sa\u00fade de S\u00e3o Jo\u00e3o, Porto 4200, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Unidade Local de Sa\u00fade de S\u00e3o Jo\u00e3o, Porto 4200, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Silva","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Unidade Local de Sa\u00fade de S\u00e3o Jo\u00e3o, Porto 4200, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-9872","authenticated-orcid":false,"given":"Guilherme","family":"Macedo","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Unidade Local de Sa\u00fade de S\u00e3o Jo\u00e3o, Porto 4200, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.3748\/wjg.v20.i23.7312","article-title":"Pathogenesis of liver cirrhosis","volume":"20","author":"Zhou","year":"2014","journal-title":"World J. Gastroenterol."},{"unstructured":"GBD 2017 Cirrhosis Collaborators (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol., 5, 245\u2013266.","key":"ref_2"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.3748\/wjg.v28.i41.5910","article-title":"Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions","volume":"28","author":"Liu","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep4.1855","article-title":"The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis","volume":"6","author":"Reiberger","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Abraldes","year":"2017","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrgastro.2009.149","article-title":"The clinical use of HVPG measurements in chronic liver disease","volume":"6","author":"Bosch","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12072-017-9795-0","article-title":"Invasive and non-invasive assessment of portal hypertension","volume":"12","author":"Leung","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/MEG.0000000000000393","article-title":"Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients: A review of the literature","volume":"27","author":"Colecchia","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1365-2036.2008.03825.x","article-title":"Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis","volume":"28","author":"Lemoine","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.21665","article-title":"Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis","volume":"45","author":"Vizzutti","year":"2007","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014Renewing consensus in portal hypertension","volume":"76","author":"Bosch","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1440-1746.2010.06325.x","article-title":"Spleen stiffness measurement using Fibroscan for the noninvasive assessment of esophageal varices in liver cirrhosis patients","volume":"26","author":"Stefanescu","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clinre.2017.11.002","article-title":"Performance of spleen stiffness measurement in prediction of clinical significant portal hypertension: A meta-analysis","volume":"42","author":"Song","year":"2018","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1055\/a-0965-0745","article-title":"Liver Stiffness Assessed by Ultrasound Shear Wave Elastography from General Electric Accurately Predicts Clinically Significant Portal Hypertension in Patients with Advanced Chronic Liver Disease","volume":"41","author":"Stefanescu","year":"2020","journal-title":"Ultraschall Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5694\/mja16.00104","article-title":"Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection","volume":"204","author":"Mitchell","year":"2016","journal-title":"Med. J. Aust."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.4254\/wjh.v7.i18.2136","article-title":"From the stomach to other organs: Helicobacter pylori and the liver","volume":"7","author":"Waluga","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1128\/CMR.00054-05","article-title":"Pathogenesis of Helicobacter pylori infection","volume":"19","author":"Kusters","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrgastro.2013.243","article-title":"Clinical effects of Helicobacter pylori outside the stomach","volume":"11","author":"Franceschi","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/08923973.2016.1247855","article-title":"Helicobacter pylori, liver cirrhosis, and portal hypertension: An updated appraisal","volume":"38","author":"Licinio","year":"2016","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_20","first-page":"158","article-title":"The effect of decrease in serum nitric oxide concentration on portal hemodynamics after Helicobacter pylori treatment: An open-label pilot study","volume":"19","author":"Serin","year":"2008","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clinre.2012.09.013","article-title":"The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 Beta, serum toll-like receptor-4 levels and Helicobacter pylori Cag A status","volume":"37","author":"Yakut","year":"2013","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"doi-asserted-by":"crossref","unstructured":"Jun, Y.K., Kim, J.W., Kim, B.G., Lee, K.L., Jung, Y.J., Kim, W., Park, H.S., Lee, D.H., and Koh, S.J. (2022). Helicobacter pylori infection is not associated with portal hypertension-related gastrointestinal complications: A meta-analysis. PLoS ONE, 17.","key":"ref_22","DOI":"10.1371\/journal.pone.0261448"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1872-034X.2007.00146.x","article-title":"Helicobacter pylori infection in hepatic encephalopathy: Relationship to plasma endotoxins and blood ammonia","volume":"37","author":"Zaki","year":"2007","journal-title":"Hepatol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0753-3322(94)90104-X","article-title":"Awakenings to the pathogenicity of urease and the requirement for continuous long term therapy","volume":"48","author":"LeVeen","year":"1994","journal-title":"Biomed. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/MCG.0000000000000108","article-title":"Does H. pylori eradication therapy benefit patients with hepatic encephalopathy?: Systematic review","volume":"48","author":"Schulz","year":"2014","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1590-8658(03)00029-X","article-title":"Helicobacter pylori infection in patients with liver cirrhosis: Facts and fictions","volume":"35","author":"Zullo","year":"2003","journal-title":"Dig. Liver Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/MEG.0000000000000928","article-title":"Helicobacter pylori infection among patients with liver cirrhosis","volume":"29","author":"Pogorzelska","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J. Hepatol."},{"doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2015). EASL Clinical Practice Guidelines: Autoimmune hepatitis. J. Hepatol., 63, 971\u20131004.","key":"ref_29","DOI":"10.1016\/j.jhep.2015.06.030"},{"doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol., 67, 145\u2013172.","key":"ref_30","DOI":"10.1016\/j.jhep.2017.03.022"},{"doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2012). EASL Clinical Practice Guidelines: Wilson\u2019s disease. J. Hepatol., 56, 671\u2013685.","key":"ref_31","DOI":"10.1016\/j.jhep.2011.11.007"},{"doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2010). EASL clinical practice guidelines for HFE hemochromatosis. J. Hepatol., 53, 3\u201322.","key":"ref_32","DOI":"10.1016\/j.jhep.2010.03.001"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16051","DOI":"10.1038\/nrdp.2016.51","article-title":"\u03b11-Antitrypsin deficiency","volume":"2","author":"Greene","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.26.11.1226","article-title":"Gastric lesions in portal hypertension: Inflammatory gastritis or congestive gastropathy?","volume":"26","author":"McCormack","year":"1985","journal-title":"Gut"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","article-title":"Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994","volume":"20","author":"Dixon","year":"1996","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/a-0859-1883","article-title":"Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019","volume":"51","author":"Libanio","year":"2019","journal-title":"Endoscopy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1440-1746.1991.tb01468.x","article-title":"The Sydney System: Histological division","volume":"6","author":"Price","year":"1991","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1083-4389.2004.00269.x","article-title":"Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis","volume":"9","author":"Martin","year":"2004","journal-title":"Helicobacter"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/MEG.0000000000000220","article-title":"Association between cirrhosis and Helicobacter pylori infection: A meta-analysis","volume":"26","author":"Feng","year":"2014","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1590-8658(03)00029-X","article-title":"Helicobacter pylori diagnosis in patients with liver cirrhosis","volume":"35","author":"Zullo","year":"2003","journal-title":"Dig. Liver Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1523-5378.2006.00380.x","article-title":"Problem of distinguishing false-positive tests from acute or transient Helicobacter pylori infections","volume":"11","author":"Nurgalieva","year":"2006","journal-title":"Helicobacter"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0168-8278(97)80459-X","article-title":"Seroprevalence and epidemiology of Helicobacter pylori infection in patients with cirrhosis","volume":"26","author":"Calvet","year":"1997","journal-title":"J. Hepatol."},{"key":"ref_43","first-page":"208","article-title":"Role of chronic Helicobacter pylori infection in hyperdynamic circulation of cirrhotic patients","volume":"49","author":"Chen","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"19530","DOI":"10.1038\/s41598-022-23746-0","article-title":"Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: A randomized controlled trial","volume":"12","author":"Yu","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/DMSO.S237866","article-title":"Relationship between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease (NAFLD) in a Developing Country: A Cross-Sectional Study","volume":"13","author":"Sabal","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/gastro\/goz058","article-title":"Effect of Helicobacter pylori-eradication therapy on hepatic steatosis in patients with non-alcoholic fatty liver disease: A randomized-controlled pilot study","volume":"8","author":"Maharshi","year":"2020","journal-title":"Gastroenterol. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"902255","DOI":"10.3389\/fmed.2022.902255","article-title":"Helicobacter pylori Infection in Cirrhotic Patients With Portal Hypertensive Gastropathy: A New Enigma?","volume":"9","author":"Alarfaj","year":"2022","journal-title":"Front. Med."},{"key":"ref_48","first-page":"597","article-title":"Correlation of portal hypertensive gastropathy with Helicobacter pylori infection, liver dysfunction, hypersplenism and oesophageal varices","volume":"77","author":"Hammad","year":"2009","journal-title":"Med. J. Cairo Univ."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.hbpd.2018.10.007","article-title":"Helicobacter pylori and portal hypertensive gastropathy","volume":"17","author":"Hu","year":"2018","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/00365520600863720","article-title":"Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: Application of plasma biomarkers","volume":"42","author":"Sipponen","year":"2007","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_51","first-page":"4129","article-title":"Prevalence of H. pylori Infection and Atrophic Gastritis in a Population-based Screening with Serum Biomarker Panel (GastroPanel(R)) in St. Petersburg","volume":"36","author":"Roman","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1515\/raon-2017-0054","article-title":"Premalignant Gastric Lesions in Patients Included in National Colorectal Cancer Screening","volume":"52","author":"Tepes","year":"2018","journal-title":"Radiol. Oncol."},{"doi-asserted-by":"crossref","unstructured":"Jeng, K.S., Chang, C.F., Sheen, I.S., Jeng, C.J., and Wang, C.H. (2022). Upper Gastrointestinal Cancer and Liver Cirrhosis. Cancers, 14.","key":"ref_53","DOI":"10.3390\/cancers14092269"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00008469-200306000-00002","article-title":"Gastric cancer prevalence in patients with liver cirrhosis","volume":"12","author":"Zullo","year":"2003","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1023\/A:1005647115304","article-title":"Gastric epithelial cell proliferation in patients with liver cirrhosis","volume":"46","author":"Zullo","year":"2001","journal-title":"Dig. Dis. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1152\/physrev.1993.73.1.79","article-title":"The biochemical basis of zinc physiology","volume":"73","author":"Vallee","year":"1993","journal-title":"Physiol. Rev."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1768\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:16:08Z","timestamp":1760105768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13061768"],"URL":"https:\/\/doi.org\/10.3390\/jcm13061768","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2024,3,19]]}}}